{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.19","upperLimit":"65.09","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Will be estimated by the number of patients who achieve a stringent complete response (sCR), complete response CR, or VGPR divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true overall \\>= VGPR will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.\n\n\\>\n\n\\> CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> Autologous Hematopoietic Stem Cell Transplantation: Undergo ASCT\n\n\\>\n\n\\> Dexamethasone: Given PO\n\n\\>\n\n\\> Ixazomib Citrate: Given PO\n\n\\>\n\n\\> Laboratory Biomarker Analysis: Correlative studies\n\n\\>\n\n\\> Pomalidomide: Given PO","id":"OG000","title":"Treatment (Ixazomib, Pomalidomide, Dexamethasone, ASCT)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"30 months","title":"Percentage of Participants With Greater Than or Equal to (>=) Very Good Partial Response (VGPR) Rate","type":"SECONDARY","unitOfMeasure":"percentage of patients"}